Motoko Tachihara
Overview
Explore the profile of Motoko Tachihara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
1163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shukuya T, Asao T, Goto Y, Mimori T, Takayama K, Kaira K, et al.
Lancet Oncol
. 2025 Mar;
26(3):331-342.
PMID: 40049197
Background: Despite the poor prognosis of advanced or recurrent thymic carcinoma, the rarity of thymic carcinoma has delayed the development and introduction of novel pharmacotherapy options. Carboplatin plus paclitaxel remains...
2.
Sato H, Nagano T, Suraya R, Hazama D, Umezawa K, Katsurada N, et al.
Respir Med
. 2025 Mar;
240:108027.
PMID: 40043918
Background: Chronic obstructive pulmonary disease (COPD) can be complicated by pulmonary hypertension (PH), impacting prognosis and quality of life. Endothelin-1 (ET-1) is implicated in PH development and elevated in COPD...
3.
Suraya R, Nagano T, Tachihara M
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002287
Mesothelioma is a highly malignant condition arising from the pleura and peritoneum that is closely related to asbestos exposure. The prognosis for this condition has traditionally been poor due to...
4.
Katsurada N, Tachihara M
Transl Cancer Res
. 2025 Jan;
13(12):6603-6607.
PMID: 39816552
No abstract available.
5.
6.
Fujimoto S, Katsurada N, Sasaki R, Ishihara T, Hazama D, Yamamoto M, et al.
Intern Med
. 2024 Nov;
PMID: 39522995
Thymic carcinoma (TC) is a rare malignancy with limited treatment options. Lenvatinib, a novel multitarget kinase inhibitor, has recently been used to treat advanced or metastatic thymic carcinoma that cannot...
7.
Tsuchiya-Kawano Y, Shiraishi Y, Tanaka K, Tachihara M, Saito R, Okamoto T, et al.
Eur J Cancer
. 2024 Oct;
212:115052.
PMID: 39357279
Background: The effect of dual immunotherapy combined with platinum-based chemotherapy on untreated brain metastases derived from non-small cell lung cancer (NSCLC) has remained unclear. Methods: This multicenter single-arm phase 2...
8.
Suraya R, Nagano T, Yumura M, Hara T, Akashi M, Yamamoto M, et al.
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273437
Even with recent advances in pathobiology and treatment options, chronic obstructive pulmonary disease (COPD) remains a major contributor to morbidity and mortality. To develop new ways of combating this disease,...
9.
Yatani A, Nagano T, Murakami S, Otoshi T, Hazama D, Katsurada N, et al.
Sci Rep
. 2024 Sep;
14(1):20505.
PMID: 39227657
The newly developed portable oxygen concentrator with an auto-demand oxygen delivery system (auto-DODS) automatically switches between 3 sensitivities according to the negative pressure gradient of inhalation and supplies oxygen only...
10.
Fujimoto S, Katsurada N, Hazama D, Yamamoto M, Nagano T, Tachihara M
Intern Med
. 2024 Jul;
64(5):749-751.
PMID: 39048364
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are key drugs for patients with EGFR mutation-positive non-small cell lung cancer, and osimertinib is the standard treatment. Although drug-induced interstitial lung...